Prediction of progression in Barrett’s esophagus: does inflammation hold the key?

Endoscopy 2021; 53(08): 782-783
DOI: 10.1055/a-1381-7899

Editorial

Referring to Peleg N et al. p. 774–781

Prasad G. Iyer

Barrett’s Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States

References
1 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30-50
2 Codipilly DC, Chandar AK, Singh S. et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. Gastroenterology 2018; 154: 2068-2086
3 Chakraborty S, Iyer PG. Predictors of progression in Barrett’s esophagus. Curr Treat Options Gastroenterol 2019; 17: 18-31
4 Peleg N, Schmilovitz-Weiss H, Shamah S. et al. Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett’s esophagus. Endoscopy 2021; 53: 774-781
5 Guo Q, Shao Z, Xu D. et al. Prognostic value of neutrophil-to-lymphocyte ratio in peripheral blood and pathological tissue in patients with esophageal squamous cell carcinoma. Medicine (Baltimore) 2020; 99: e21306
6 Pirozzolo G, Gisbertz SS, Castoro C. et al. Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis. J Thorac Dis 2019; 11: 3136-3145
7 Templeton AJ, McNamara MG, Seruga B. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124
8 Parasa S, Vennalaganti S, Gaddam S. et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology 2018; 154: 1282-1289